As only specific missense mutations in the motor domain of MYO5B cause cholestasis, gene addition therapy of such a smaller splice variant, if functional, may in theory be an option, but only in combination with deleting the expression of the endogenous mutated MYO5B protein. This evidence concerns the gene MYO5B and cholestasis.